Posted on May 11, 2019 by Sitemaster
The results of the 1,125-patient, randomized, double-blind ENZAMET trial are to be reported in a late-breaking abstract at the upcoming annual meeting of the American Society for Clinical Oncology (ASCO) in Chicago. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, ENZAMET, enzlutamide, hormone-sensitive, latitude, metastatic, mHSPC, outcome | 9 Comments »
Posted on April 19, 2019 by Sitemaster
Long-term follow-up data from the LATITUDE trial have now been published by Fizazi et al. in Lancet Oncology. … READ MORE …
Filed under: Uncategorized | Tagged: "high risk", abiraterone, ADT, hormone-sensitive, latitude, metastatic, newly diagnosed, survival | 4 Comments »
Posted on January 10, 2018 by Sitemaster
A newly published paper in The Lancet Oncology has provided early data from the LATITUDE trial on patient-reported outcomes (PROs) and health-related quality of life (HRQoL) for men with newly diagnosed, high-risk, metastatic, castration-naive prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: adverse, effect, latitude, life, pain, quality, risk, trial | Leave a comment »
Posted on October 11, 2017 by Sitemaster
So the discussion about how to use the data from the CHAARTED, STAMPEDE, and LATITUDE trials in the initial treatment of men with node-positive and metastatic hormone-sensitive and castration-resistant prostate cancer continues to be an issue of intense discussion among urologic and medical oncologists. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: CHAARTED, hormone-sensitive, latitude, metastatic, mHSPC, nmHSPC, non-metastatic, STAMPEDE | 1 Comment »
Posted on September 3, 2017 by Sitemaster
So about 3 years after the initial report of the results from the CHAARTED trial, 2 years after the initial report from the ADT + docetaxel arm of the STAMPEDE trial, and 3 months after the reports and publication of data from the LATITUDE trial and the ADT + abiraterone arm of the STAMPEDE trial, … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: hormone-resistant, hormone-sensistive, latitude, mCRPC, metastatic, mHSPC, STAMPEDE, Treatment | Leave a comment »
Posted on June 5, 2017 by Sitemaster
So one of the benefits of being at the annual ASCO meeting is that you get to talk to lots of medical oncologists who specialize in treating prostate cancer — if you are patient and polite. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, hromone-sensitive, latitude, metastatic, STAMPEDE | 6 Comments »
Posted on April 27, 2017 by Sitemaster
According to an e-mail your sitemaster has just received from ASCO, we will be getting the initial results from the LATITUDE trial at the upcoming ASCO meeting in June this year. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, latitude, outcome, trial | 5 Comments »
Posted on January 13, 2014 by Sitemaster
A newly published paper in the journal Nutrients doesn’t tell us anything really new about the likely correlations between nutrition and risk for prostate cancer, but it does offer us some interesting information about the time frame over which such correlations may take effect. … READ MORE …
Filed under: Diagnosis, Prevention, Risk | Tagged: alcohol, animal, Diagnosis, diet, latitude, nutrition, risk | 2 Comments »
THE "NEW" PROSTATE CANCER INFOLINK 